Capricor Therapeutics Inc Overview
Industry: Biotechnology
Sector: Healthcare
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California. Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardia Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Capricor Therapeutics Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Exhibit 99.1 Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update ● Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon ● HOPE-3 Phase...
What changed
- Review the SEC source filing for the full reported results and management commentary.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
May 13, 2026
SEC filing
8-K
May 12, 2026
SEC filing
10-K
Mar 17, 2026
SEC filing
8-K
Mar 12, 2026
Earnings release
Earnings release
Mar 12, 2026
SEC filing
8-K
Nov 10, 2025
Earnings release
Earnings release
Nov 10, 2025
SEC filing
10-Q
Nov 10, 2025
SEC filing
10-Q
Aug 11, 2025
SEC filing
8-K
Aug 11, 2025
Earnings release
Earnings release
Aug 11, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
CAPR Stock Eyes 1st Weekly Gain In 5 Weeks: Capricor’s DMD Therapy Faces FDA Panel Review Next Week, Retail Sees 'Excellent Opportunity'
Headline from Yahoo Finance: CAPR Stock Eyes 1st Weekly Gain In 5 Weeks: Capricor’s DMD Therapy Faces FDA Panel Review Next Week, Retail Sees 'Excellent Opportunity'.
This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy?
Headline from Yahoo Finance: This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy?
Cantor Fitzgerald reiterates Overweight on Capricor stock at $62
Headline from Investing.com: Cantor Fitzgerald reiterates Overweight on Capricor stock at $62.
Earnings Per Share
Score 3.00/5
Capricor Therapeutics Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score 0.51/5
Capricor Therapeutics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 0.72/5
Capricor Therapeutics Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 2.67/5
Capricor Therapeutics Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios